Literature DB >> 15509530

Lack of the growth factor midkine enhances survival against cisplatin-induced renal damage.

Hanayo Kawai1, Waichi Sato, Yukio Yuzawa, Tomoki Kosugi, Seiichi Matsuo, Yoshifumi Takei, Kenji Kadomatsu, Takashi Muramatsu.   

Abstract

Although cisplatin acts directly on proximal tubule epithelial cells and causes cell death, little is known regarding the biological significance of its secondary effects, such as inflammation. The growth factor midkine is highly expressed in the proximal tubule and exerts ambivalent activities as to cisplatin nephrotoxicity, ie, anti-apoptotic and chemotactic ones. Here we report that midkine-deficient mice show a significantly higher survival rate than wild-type mice. The levels of blood urea nitrogen and tubular degeneration and apoptosis were higher in wild-type mice despite the anti-apoptotic activity of midkine. We found that recruitment of neutrophils was more enhanced in wild-type mice, this being consistent with the chemotactic activity of midkine. Midkine expression in wild-type mice persisted for 24 hours, and then dramatically decreased. Preadministration of midkine anti-sense oligodeoxyribonucleotide to wild-type mice suppressed midkine expression, and consequently neutrophil infiltration. It is of note that neutrophil infiltration, apoptosis, and elevation of blood urea nitrogen became conspicuous sequentially, namely 1, 2, and 3 days after cisplatin administration, respectively. These findings suggest that early molecular events involving midkine induce inflammatory response and their circuits eventually enhance the death of the proximal tubule epithelial cells. The results indicate the crucial role of inflammation in cisplatin-induced renal damage, and provide a candidate molecular target for its prevention.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15509530      PMCID: PMC1618674          DOI: 10.1016/S0002-9440(10)63417-7

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  38 in total

1.  cDNA cloning and sequencing of a new gene intensely expressed in early differentiation stages of embryonal carcinoma cells and in mid-gestation period of mouse embryogenesis.

Authors:  K Kadomatsu; M Tomomura; T Muramatsu
Journal:  Biochem Biophys Res Commun       Date:  1988-03-30       Impact factor: 3.575

2.  Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury.

Authors:  J Deng; Y Kohda; H Chiao; Y Wang; X Hu; S M Hewitt; T Miyaji; P McLeroy; B Nibhanupudy; S Li; R A Star
Journal:  Kidney Int       Date:  2001-12       Impact factor: 10.612

3.  Antisense oligodeoxynucleotide targeted to Midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells.

Authors:  Y Takei; K Kadomatsu; S Matsuo; H Itoh; K Nakazawa; S Kubota; T Muramatsu
Journal:  Cancer Res       Date:  2001-12-01       Impact factor: 12.701

4.  Gamma-glutamyl transpeptidase-deficient mice are resistant to the nephrotoxic effects of cisplatin.

Authors:  M H Hanigan; E D Lykissa; D M Townsend; C N Ou; R Barrios; M W Lieberman
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

5.  Midkine is involved in kidney development and in its regulation by retinoids.

Authors:  José Vilar; Claude Lalou; Jean-Paul Duong Van Huyen; Stéphanie Charrin; Sylvie Hardouin; Daniel Raulais; Claudie Merlet-Bénichou; Martine Leliévre-Pégorier
Journal:  J Am Soc Nephrol       Date:  2002-03       Impact factor: 10.121

6.  Haptotactic migration induced by midkine. Involvement of protein-tyrosine phosphatase zeta. Mitogen-activated protein kinase, and phosphatidylinositol 3-kinase.

Authors:  M Qi; S Ikematsu; N Maeda; K Ichihara-Tanaka; S Sakuma; M Noda; T Muramatsu; K Kadomatsu
Journal:  J Biol Chem       Date:  2001-05-11       Impact factor: 5.157

7.  TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity.

Authors:  Ganesan Ramesh; W Brian Reeves
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

Review 8.  Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis.

Authors:  Takashi Muramatsu
Journal:  J Biochem       Date:  2002-09       Impact factor: 3.387

9.  Renal uptake of an 18-mer phosphorothioate oligonucleotide.

Authors:  R Oberbauer; G F Schreiner; T W Meyer
Journal:  Kidney Int       Date:  1995-10       Impact factor: 10.612

10.  Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells.

Authors:  Danyelle M Townsend; Mei Deng; Lei Zhang; Maia G Lapus; Marie H Hanigan
Journal:  J Am Soc Nephrol       Date:  2003-01       Impact factor: 10.121

View more
  20 in total

Review 1.  Restoring the renal microvasculature to treat chronic kidney disease.

Authors:  David A Long; Jill T Norman; Leon G Fine
Journal:  Nat Rev Nephrol       Date:  2012-02-07       Impact factor: 28.314

2.  Midkine as a potential diagnostic marker in epithelial ovarian cancer for cisplatin/paclitaxel combination clinical therapy.

Authors:  Xiaoqing Wu; Xiaogai Zhi; Minghua Ji; Qingling Wang; Yujuan Li; Jingyan Xie; Shuli Zhao
Journal:  Am J Cancer Res       Date:  2015-01-15       Impact factor: 6.166

3.  Growth factor Midkine is involved in the pathogenesis of renal injury induced by protein overload containing endotoxin.

Authors:  Kiyonari Kato; Tomoki Kosugi; Waichi Sato; Hanayo Arata-Kawai; Takenori Ozaki; Naotake Tsuboi; Isao Ito; Hideo Tawada; Yukio Yuzawa; Seiichi Matsuo; Kenji Kadomatsu; Shoichi Maruyama
Journal:  Clin Exp Nephrol       Date:  2011-03-01       Impact factor: 2.801

4.  Efficacy of urinary midkine as a biomarker in patients with acute kidney injury.

Authors:  Hiroki Hayashi; Waichi Sato; Tomoki Kosugi; Kunihiro Nishimura; Daisuke Sugiyama; Naoko Asano; Shinya Ikematsu; Kimihiro Komori; Kimitoshi Nishiwaki; Kenji Kadomatsu; Seiichi Matsuo; Shoichi Maruyama; Yukio Yuzawa
Journal:  Clin Exp Nephrol       Date:  2016-08-16       Impact factor: 2.801

Review 5.  From top to bottom: midkine and pleiotrophin as emerging players in immune regulation.

Authors:  Noah Sorrelle; Adrian T A Dominguez; Rolf A Brekken
Journal:  J Leukoc Biol       Date:  2017-03-29       Impact factor: 4.962

6.  Growth factor midkine is involved in the pathogenesis of diabetic nephropathy.

Authors:  Tomoki Kosugi; Yukio Yuzawa; Waichi Sato; Hanayo Kawai; Seiichi Matsuo; Yoshifumi Takei; Takashi Muramatsu; Kenji Kadomatsu
Journal:  Am J Pathol       Date:  2006-01       Impact factor: 4.307

Review 7.  Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases.

Authors:  D R Jones
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

8.  Midkine accumulated in nucleolus of HepG2 cells involved in rRNA transcription.

Authors:  Li-Cheng Dai; Jian-Zhong Shao; Li-Shan Min; Yong-Tao Xiao; Li-Xin Xiang; Zhi-Hong Ma
Journal:  World J Gastroenterol       Date:  2008-10-28       Impact factor: 5.742

9.  Midkine inhibitors: application of a simple assay procedure to screening of inhibitory compounds.

Authors:  Takashi Matsui; Keiko Ichihara-Tanaka; Chen Lan; Hisako Muramatsu; Toshiharu Kondou; Chizuru Hirose; Sadatoshi Sakuma; Takashi Muramatsu
Journal:  Int Arch Med       Date:  2010-06-21

Review 10.  Midkine in nephrogenesis, hypertension and kidney diseases.

Authors:  Waichi Sato; Yuka Sato
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.